Compare Stocks: XBIO, ESLA, ATOS, and NEUP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$2.34 +3.1%	$2.39	$1.70 ▼ $19.35	$23.35M	1.28	116,973 shs	74,265 shs
ESLA Estrella Immunopharma	$0.47 -1.5%	$0.66	$0.43 ▼ $3.15	$20.36M	0.93	96,691 shs	14,485 shs
NEUP Neuphoria Therapeutics	$3.47 -1.1%	$3.79	$3.19 ▼ $21.40	$18.77M	0.75	93,770 shs	12,581 shs
XBIO Xenetic Biosciences	$2.24	$3.26	$1.87 ▼ $13.93	$5.13M	2.2	43,402 shs	43,201 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	+16.41%	+10.73%	-6.20%	+7.08%	-83.48%
ESLA Estrella Immunopharma	+1.78%	+0.85%	-31.31%	-51.65%	-64.55%
NEUP Neuphoria Therapeutics	-1.40%	-3.84%	-7.39%	+3.85%	-74.66%
XBIO Xenetic Biosciences	-3.45%	-9.31%	-47.04%	-20.82%	-27.48%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATOS Atossa Genetics	$2.34 +3.1%	$2.39	$1.70 ▼ $19.35	$23.35M	1.28	116,973 shs	74,265 shs
ESLA Estrella Immunopharma	$0.47 -1.5%	$0.66	$0.43 ▼ $3.15	$20.36M	0.93	96,691 shs	14,485 shs
NEUP Neuphoria Therapeutics	$3.47 -1.1%	$3.79	$3.19 ▼ $21.40	$18.77M	0.75	93,770 shs	12,581 shs
XBIO Xenetic Biosciences	$2.24	$3.26	$1.87 ▼ $13.93	$5.13M	2.2	43,402 shs	43,201 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATOS Atossa Genetics	+16.41%	+10.73%	-6.20%	+7.08%	-83.48%
ESLA Estrella Immunopharma	+1.78%	+0.85%	-31.31%	-51.65%	-64.55%
NEUP Neuphoria Therapeutics	-1.40%	-3.84%	-7.39%	+3.85%	-74.66%
XBIO Xenetic Biosciences	-3.45%	-9.31%	-47.04%	-20.82%	-27.48%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATOS Atossa Genetics	2.20	Hold	$20.33	768.95% Upside
ESLA Estrella Immunopharma	2.00	Hold	$8.00	1,609.40% Upside
NEUP Neuphoria Therapeutics	1.67	Reduce	$7.00	101.73% Upside
XBIO Xenetic Biosciences	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest XBIO, ESLA, ATOS, and NEUP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/24/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/8/2026	ATOS Atossa Genetics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/8/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	NEUP Neuphoria Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/25/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	ESLA Estrella Immunopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	XBIO Xenetic Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/7/2026	ATOS Atossa Genetics	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$12.00

(Data available from 10/2/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$4.57 per share	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	($0.27) per share	N/A
NEUP Neuphoria Therapeutics	$1.17M	16.05	N/A	N/A	$4.55 per share	0.76
XBIO Xenetic Biosciences	$2.98M	1.72	N/A	N/A	$3.23 per share	0.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATOS Atossa Genetics	-$34.77M	-$3.11	N/A	N/A	N/A	N/A	-102.99%	-85.78%	11/11/2026 (Estimated)
ESLA Estrella Immunopharma	-$13.06M	-$0.24	N/A	N/A	N/A	N/A	N/A	-328.72%	12/2/2026 (Estimated)
NEUP Neuphoria Therapeutics	-$13.45M	-$6.22	N/A	N/A	N/A	N/A	-38.31%	-28.92%	10/5/2026 (Estimated)
XBIO Xenetic Biosciences	-$2.68M	-$1.16	N/A	N/A	N/A	-75.90%	-40.62%	-34.97%	11/6/2026 (Estimated)

Latest XBIO, ESLA, ATOS, and NEUP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
10/5/2026	Q4 2026	NEUP Neuphoria Therapeutics	-$1.58	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	ESLA Estrella Immunopharma	-$0.09	-$0.05	+$0.04	-$0.05	N/A	N/A
8/7/2026	Q2 2026	ATOS Atossa Genetics	-$1.02	-$0.95	+$0.07	-$0.95	N/A	N/A
8/6/2026	Q2 2026	XBIO Xenetic Biosciences	N/A	-$0.41	N/A	-$0.41	N/A	$0.66 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
ESLA Estrella Immunopharma	N/A	N/A	N/A	N/A	N/A
NEUP Neuphoria Therapeutics	N/A	N/A	N/A	N/A	N/A
XBIO Xenetic Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATOS Atossa Genetics	N/A	5.69	5.69
ESLA Estrella Immunopharma	N/A	0.20	0.20
NEUP Neuphoria Therapeutics	N/A	27.83	27.83
XBIO Xenetic Biosciences	N/A	7.43	7.43

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATOS Atossa Genetics	12.74%
ESLA Estrella Immunopharma	0.35%
NEUP Neuphoria Therapeutics	15.90%
XBIO Xenetic Biosciences	15.12%

Insider Ownership

Company	Insider Ownership
ATOS Atossa Genetics	9.80%
ESLA Estrella Immunopharma	5.80%
NEUP Neuphoria Therapeutics	1.55%
XBIO Xenetic Biosciences	7.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATOS Atossa Genetics	14	9.98 million	9.00 million	Optionable
ESLA Estrella Immunopharma	N/A	43.50 million	40.98 million	Not Optionable
NEUP Neuphoria Therapeutics	8	5.41 million	5.33 million	N/A
XBIO Xenetic Biosciences	2	2.29 million	2.12 million	Not Optionable

XBIO, ESLA, ATOS, and NEUP Headlines

Recent News About These Companies

Financial Contrast: Xenetic Biosciences (NASDAQ:XBIO) & Allarity Therapeutics (NASDAQ:ALLR)

September 27, 2026 | defenseworld.netD

Reviewing Allarity Therapeutics (NASDAQ:ALLR) & Xenetic Biosciences (NASDAQ:XBIO)

September 27, 2026 | americanbankingnews.com

Xenetic Biosciences (NASDAQ: XBIO) to Acquire 85% Stake in Santersus AG in All-Stock Deal

September 18, 2026 | kalkinemedia.comK

Xenetic To Acquire Santersus In All-Stock Deal To Advance NET-Focused Pipeline

September 17, 2026 | rttnews.com

Xenetic Biosciences y Santersus AG acuerdan crear un líder global en terapias contra las NET

September 16, 2026 | es.finance.yahoo.com

Xenetic Biosciences announces all-stock merger with Santersus, leaving existing shareholders with 15% stake

September 16, 2026 | msn.com

Xenetic Biosciences, Inc. (XBIO) M&A Call Prepared Remarks Transcript

September 16, 2026 | seekingalpha.com

Xenetic Biosciences to acquire Santersus AG in all-stock deal

September 16, 2026 | streetinsider.com

Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

September 16, 2026 | accessnewswire.comA

Xenetic Biosciences Inc.

September 5, 2026 | barrons.com

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

August 7, 2026 | accessnewswire.comA

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of ...

June 4, 2026 | finance.yahoo.com

Xenetic Biosciences, Inc. Announces That Its Collaboration Partner Received Approval From the Israeli Ministry of Health to Conduct Exploratory, Investigator Initiated Study of DNase I In Combination With Anti-CD19 CAR T Cells in Large B-Cell Lymphoma

June 4, 2026 | accessnewswire.comA

Xenetic Biosciences Showcases Compelling ASCO 2026 Data Demonstrating DNase I Significantly Enhances CAR-T Cell Persistence, Tumor Control, and Survival

June 1, 2026 | accessnewswire.comA

Xenetic Biosciences Reports First Quarter 2026 Financial Results and Highlights Continued Advancement of DNase Oncology Platform

May 13, 2026 | accessnewswire.comA

Xenetic Biosciences: Q1 Earnings Snapshot

May 12, 2026 | wtop.comW

Xenetic Biosciences Grants Equity Award to Interim CEO

April 27, 2026 | theglobeandmail.com

Xenetic Biosciences, Inc. Announces Abstract Acceptance for Presentation at the 2026 ASCO Annual Meeting

April 22, 2026 | accessnewswire.comA

Xenetic Biosciences, Inc. Reports Full Year 2025 Financial Results

March 13, 2026 | accessnewswire.comA

Xenetic Biosciences, Inc. Announces Adjournment of 2025 Annual Meeting

December 11, 2025 | accessnewswire.comA

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

XBIO, ESLA, ATOS, and NEUP Company Descriptions

Atossa Genetics NASDAQ:ATOS

$2.34 +0.07 (+3.08%)

Closing price 04:00 PM Eastern

Extended Trading

$2.33 -0.01 (-0.43%)

As of 05:17 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

Estrella Immunopharma NASDAQ:ESLA

$0.47 -0.01 (-1.47%)

Closing price 04:00 PM Eastern

Extended Trading

$0.47 +0.00 (+0.64%)

As of 04:04 PM Eastern

Estrella Immunopharma, Inc., a preclinical-stage biopharmaceutical company, develops T-cell therapies for blood cancers and solid tumors in the United States. The company's lead product candidates include EB103 for the treatment of diffuse large B-cell lymphoma and is in pre clinical trial; and EB104 to treat diffuse large B-cell lymphoma and acute lymphocytic leukemia. It has a collaborative partnership with Imugene Limited for the development of solid tumor treatments using Imugene's product candidate CF33-CD19t in conjunction with EB103. Estrella Immunopharma, Inc. is based in EmeryVille, California.

Neuphoria Therapeutics NASDAQ:NEUP

$3.47 -0.04 (-1.14%)

Closing price 03:59 PM Eastern

Extended Trading

$3.46 -0.01 (-0.14%)

As of 04:10 PM Eastern

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Xenetic Biosciences NASDAQ:XBIO

$2.24 0.00 (0.00%)

Closing price 04:00 PM Eastern

Extended Trading

$2.24 +0.00 (+0.22%)

As of 04:10 PM Eastern

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XBIO, ESLA, ATOS, and NEUP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XBIO, ESLA, ATOS, and NEUP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XBIO, ESLA, ATOS, and NEUP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XBIO, ESLA, ATOS, and NEUP Company Descriptions

Atossa Genetics NASDAQ:ATOS

Estrella Immunopharma NASDAQ:ESLA

Neuphoria Therapeutics NASDAQ:NEUP

Xenetic Biosciences NASDAQ:XBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest XBIO, ESLA, ATOS, and NEUP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest XBIO, ESLA, ATOS, and NEUP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

XBIO, ESLA, ATOS, and NEUP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

XBIO, ESLA, ATOS, and NEUP Company Descriptions

Atossa Genetics NASDAQ:ATOS

Estrella Immunopharma NASDAQ:ESLA

Neuphoria Therapeutics NASDAQ:NEUP

Xenetic Biosciences NASDAQ:XBIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools